These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

273 related items for PubMed ID: 17522247

  • 1. The effectiveness of darbepoetin alfa administered every 3 weeks on hematologic outcomes and quality of life in older patients with chemotherapy-induced anemia.
    Boccia R, Lillie T, Tomita D, Balducci L.
    Oncologist; 2007 May; 12(5):584-93. PubMed ID: 17522247
    [Abstract] [Full Text] [Related]

  • 2. Darbepoetin alfa administered every three weeks is effective for the treatment of chemotherapy-induced anemia.
    Boccia R, Malik IA, Raja V, Kahanic S, Liu R, Lillie T, Tomita D, Clowney B, Silberstein P.
    Oncologist; 2006 Apr; 11(4):409-17. PubMed ID: 16614237
    [Abstract] [Full Text] [Related]

  • 3. Darbepoetin alfa administered every three weeks (Q3W) in anemic cancer patients receiving chemotherapy (CT).
    Martelli O, Garassino M, Sacchetta S, Caristo R, Zivi A, Cerbone L, Mancuso A.
    Anticancer Res; 2008 Apr; 28(3B):1767-71. PubMed ID: 18630457
    [Abstract] [Full Text] [Related]

  • 4. A randomized comparison of every-2-week darbepoetin alfa and weekly epoetin alfa for the treatment of chemotherapy-induced anemia in patients with breast, lung, or gynecologic cancer.
    Schwartzberg LS, Yee LK, Senecal FM, Charu V, Tomita D, Wallace J, Rossi G.
    Oncologist; 2004 Apr; 9(6):696-707. PubMed ID: 15561813
    [Abstract] [Full Text] [Related]

  • 5. Randomized, double-blind, placebo-controlled trial of every-3-week darbepoetin alfa 300 micrograms for treatment of chemotherapy-induced anemia.
    Hernandez E, Ganly P, Charu V, Dibenedetto J, Tomita D, Lillie T, Taylor K, ARANESP 20030232 Study Group.
    Curr Med Res Opin; 2009 Sep; 25(9):2109-20. PubMed ID: 19601709
    [Abstract] [Full Text] [Related]

  • 6. A randomized, open-label, multicenter trial of immediate versus delayed intervention with darbepoetin alfa for chemotherapy-induced anemia.
    Charu V, Saidman B, Ben-Jacob A, Justice GR, Maniam AS, Tomita D, Rossi G, Rearden T, Glaspy J.
    Oncologist; 2007 Oct; 12(10):1253-63. PubMed ID: 17962619
    [Abstract] [Full Text] [Related]

  • 7. Assessment of hematologic effects and fatigue in cancer patients with chemotherapy-induced anemia given darbepoetin alfa every two weeks.
    Vadhan-Raj S, Mirtsching B, Charu V, Terry D, Rossi G, Tomita D, McGuire WP.
    J Support Oncol; 2003 Oct; 1(2):131-8. PubMed ID: 15352656
    [Abstract] [Full Text] [Related]

  • 8. A randomized, controlled trial comparing darbepoetin alfa correction/maintenance dosing with weekly dosing for treating chemotherapy-induced anemia.
    Kotasek D, Canon JL, Mateos MV, Hedenus M, Rossi G, Taylor K.
    Curr Med Res Opin; 2007 Jun; 23(6):1387-401. PubMed ID: 17559735
    [Abstract] [Full Text] [Related]

  • 9. Darbepoetin alfa 300 or 500 μg once every 3 weeks with or without intravenous iron in patients with chemotherapy-induced anemia.
    Auerbach M, Silberstein PT, Webb RT, Averyanova S, Ciuleanu TE, Shao J, Bridges K.
    Am J Hematol; 2010 Sep; 85(9):655-63. PubMed ID: 20661916
    [Abstract] [Full Text] [Related]

  • 10. Use of latent growth curve models for assessing the effects of darbepoetin alfa on hemoglobin and fatigue.
    Stull DE, Vernon MK, Legg JC, Viswanathan HN, Fairclough D, Revicki DA.
    Contemp Clin Trials; 2010 Mar; 31(2):172-9. PubMed ID: 20060499
    [Abstract] [Full Text] [Related]

  • 11. Darbepoetin alfa administered every 4 weeks for anemia in patients with advanced prostate cancer.
    Beer TM, Bergenstock M, Birt K, Higano CS.
    Clin Genitourin Cancer; 2007 Jun; 5(5):329-33. PubMed ID: 17645830
    [Abstract] [Full Text] [Related]

  • 12. Antianemic effect of once weekly regimen of epoetin alfa 40,000 units in anemic cancer patients receiving chemotherapy.
    Voravud N, Sriuranpong V, Suwanrusme H.
    J Med Assoc Thai; 2007 Jun; 90(6):1082-8. PubMed ID: 17624200
    [Abstract] [Full Text] [Related]

  • 13. Efficacy and safety of every-2-week darbepoetin alfa in patients with anemia of cancer: a controlled, randomized, open-label phase II trial.
    Charu V, Belani CP, Gill AN, Bhatt M, Tomita D, Rossi G, Ben-Jacob A.
    Oncologist; 2007 Jun; 12(6):727-37. PubMed ID: 17602062
    [Abstract] [Full Text] [Related]

  • 14. Randomized, double-blind, placebo-controlled study to evaluate the effect of two dosing regimens of darbepoetin alfa in patients with heart failure and anaemia.
    van Veldhuisen DJ, Dickstein K, Cohen-Solal A, Lok DJ, Wasserman SM, Baker N, Rosser D, Cleland JG, Ponikowski P.
    Eur Heart J; 2007 Sep; 28(18):2208-16. PubMed ID: 17681958
    [Abstract] [Full Text] [Related]

  • 15. Randomized comparison of every-2-week darbepoetin alfa and weekly epoetin alfa for the treatment of chemotherapy-induced anemia: the 20030125 Study Group Trial.
    20030125 Study Group TrialUniversity of California Los Angeles School of Medicine, Los Angeles, CA 90095, USA. jglaspy@mednet.ucla.edu, Glaspy J, Vadhan-Raj S, Patel R, Bosserman L, Hu E, Lloyd RE, Boccia RV, Tomita D, Rossi G.
    J Clin Oncol; 2006 May 20; 24(15):2290-7. PubMed ID: 16710026
    [Abstract] [Full Text] [Related]

  • 16. Effectiveness of darbepoetin alfa versus epoetin alfa for the treatment of chemotherapy induced anemia in patients with gynecologic malignancies.
    Case AS, Rocconi RP, Kilgore LC, Barnes MN.
    Gynecol Oncol; 2006 Jun 20; 101(3):499-502. PubMed ID: 16406064
    [Abstract] [Full Text] [Related]

  • 17. Every-2-week darbepoetin alfa is comparable to rHuEPO in treating chemotherapy-induced anemia. Results of a combined analysis.
    Mirtsching B, Charu V, Vadhan-Raj S, Colowick AB, Rossi G, Tomita D, McGuire WP.
    Oncology (Williston Park); 2002 Oct 20; 16(10 Suppl 11):31-6. PubMed ID: 12435171
    [Abstract] [Full Text] [Related]

  • 18. Assessing symptom burden using the M. D. Anderson symptom inventory in patients with chemotherapy-induced anemia: results of a multicenter, open-label study (SURPASS) of patients treated with darbepoetin-alpha at a dose of 200 microg every 2 weeks.
    Gabrilove JL, Perez EA, Tomita DK, Rossi G, Cleeland CS.
    Cancer; 2007 Oct 01; 110(7):1629-40. PubMed ID: 17694552
    [Abstract] [Full Text] [Related]

  • 19. Randomized phase 2 dose-finding study of weekly administration of darbepoetin alpha in anemic patients with lung or ovarian cancer receiving multicycle platinum-containing chemotherapy.
    Ichinose Y, Seto T, Nishiwaki Y, Ohe Y, Yamada Y, Takeda K, Saijo N, Hotta T.
    Jpn J Clin Oncol; 2010 Jun 01; 40(6):521-9. PubMed ID: 20508073
    [Abstract] [Full Text] [Related]

  • 20. Evaluation of clinical use and effectiveness of darbepoetin alfa in cancer patients with chemotherapy-induced anemia.
    Bustos A, Álvarez R, Aramburo PM, Carabantes F, Díaz N, Florián J, Lázaro M, de Segovia JM, Gasquet JA, Alegre A, RADAR Study Group.
    Curr Med Res Opin; 2012 Jan 01; 28(1):57-67. PubMed ID: 22070513
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.